While discussing Amarin, will the company find a partner to help launch Vascepa, or perhaps a buyer?
I can't mention Vivus and ignore Arena Pharmaceuticals (ARNA), which is expected to receive DEA scheduling for Belviq before the end of the year so that the obesity drug can be launched early in 2013.
Will Peregrine Pharmaceuticals (PPHM) sign a partner before starting the bavituximab phase III lung cancer study at year's end, as promised?Same goes for YM BioSciences (YMI): Where is the promised partner to co-develop the myelobfibrosis drug CYT387? Can Idenix Pharmaceuticals (IDIX) gather enough safety data to convince FDA to lift the clinical hold on its hepatitis C drugs? Will Achillion Pharmaceuticals (ACHN), which like Idenix is seeking partners or buyers for its hepatitis C drugs, finally change its Facebook status to "In a Relationship?" --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts